Trial: 202108130

A Phase III, Double-blind, Randomised Study to Assess Switchingto
AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors(Palbociclib or
Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitorsin HR+/HER2- MBC Patients with
Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L
Treatment with NSAI +CDK4/6 Inhibitor


III (Cancer Control)

Principal Investigator

Ma, Cynthia

Disease Site


Learn more about this study at: